<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696029</url>
  </required_header>
  <id_info>
    <org_study_id>BCC016</org_study_id>
    <nct_id>NCT04696029</nct_id>
  </id_info>
  <brief_title>DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma</brief_title>
  <official_title>Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle SaulnierSholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as&#xD;
      Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory&#xD;
      Medulloblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose&#xD;
      of 2500 mg/m2 BID on each day of study.&#xD;
&#xD;
      Subjects will be evaluated in 3 Cohorts:&#xD;
&#xD;
      Cohort 1: Molecular High Risk Medulloblastoma Cohort 2: Molecular Very High Risk&#xD;
      Medulloblastoma Cohort 3: Relapsed/Refractory Medulloblastoma&#xD;
&#xD;
      A total of 118 subjects across all cohorts will be enrolled to ensure that there will be 107&#xD;
      evaluable subjects (32-39 per cohort)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">March 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with event free survival (EFS) during study</measure>
    <time_frame>2 years plus 5 years follow up</time_frame>
    <description>o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2-year progression-free survival rate (PFS) compared to relevant historical controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of time that participants experience Overall Survival (OS)</measure>
    <time_frame>7 years</time_frame>
    <description>o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Overall Response Rate (ORR) of Participants using Modified RANO Criteria</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon Response Rate for patients with non-bulky residual disease present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years plus 30 days</time_frame>
    <description>To develop a complete safety and tolerability profile of difluoromethylornithine (DFMO) in pediatric and young adult subjects with medulloblastoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine amount of DFMO in the CSF at 3 hours post dose</measure>
    <time_frame>2 years</time_frame>
    <description>o To measure CSF penetration after DFMO administration in pediatric subjects with medulloblastoma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>Difluoromethylornithine (DFMO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 2500 mg/m2 BID on each day of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluoromethylornithine</intervention_name>
    <description>DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.&#xD;
The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).&#xD;
The tablets are to be stored at room temperature (20-250C).</description>
    <arm_group_label>Difluoromethylornithine (DFMO)</arm_group_label>
    <other_name>Eflornithine</other_name>
    <other_name>DFMO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 0-21 years of age at diagnosis&#xD;
&#xD;
          2. Pathology All patients must either have a pathologically confirmed diagnosis of&#xD;
             medulloblastoma with molecular grouping identified by either Nanostring or methylation&#xD;
             profiling.&#xD;
&#xD;
             Cohort 1- Molecular High Risk:&#xD;
&#xD;
               -  Metastatic non-MYC amplified Group 3&#xD;
&#xD;
               -  Metastatic Group 4&#xD;
&#xD;
               -  Metastatic non-WNT/non-SHH (Must be non-MYC amplified)&#xD;
&#xD;
             Cohort 2- Molecular Very High Risk&#xD;
&#xD;
               -  Metastatic OR MYCN amplified OR TP53 mutant non-infant (&gt;3 yrs) SHH&#xD;
&#xD;
               -  MYC amplified Group 3&#xD;
&#xD;
               -  Non-WNT, non-SHH infant (&lt; 3 yrs)&#xD;
&#xD;
             Cohort 3: Relapsed/Refractory Medulloblastoma&#xD;
&#xD;
          3. Pre-enrollment tumor survey:&#xD;
&#xD;
             Prior to enrollment on this study, a determination of mandatory disease staging must&#xD;
             be performed:&#xD;
&#xD;
               -  Tumor imaging studies including: Brain and spine MRI&#xD;
&#xD;
               -  Lumbar Puncture only if previously positive&#xD;
&#xD;
               -  Bone Marrow aspiration/biopsy only if previously positive&#xD;
&#xD;
               -  This disease assessment is required for eligibility and preferably should be done&#xD;
                  within 2 weeks prior to first dose of study drug, but must be done within a&#xD;
                  maximum of 4 weeks before first dose of study drug.&#xD;
&#xD;
          4. Disease Status: Subjects must have no evidence of disease, or stable* residual&#xD;
             nonbulky** disease.&#xD;
&#xD;
             *Stable residual disease defined as non-progression over 2 separate imaging studies at&#xD;
             least 6 weeks apart&#xD;
&#xD;
             **Non-bulky disease defined as maximal cross-sectional area &lt; 3cm^2 at enrollment.&#xD;
             Patients with leptomeningeal disease are allowed to participate on study.&#xD;
&#xD;
          5. Timing from prior therapy:&#xD;
&#xD;
             Enrollment (first dose of DFMO) no later than 60 days after last dose of conventional&#xD;
             chemotherapy. Patients who have undergone high dose chemotherapy (HDCT) with&#xD;
             autologous stem cell transplantation (SCT) are eligible if more than 45 days have&#xD;
             elapsed since date of last SCT.&#xD;
&#xD;
          6. Patients must have a Lansky or Karnofsky Performance Scale score of ≥ 50% (see&#xD;
             Appendix II) and patients must have a life expectancy of ≥ 2 months.&#xD;
&#xD;
          7. All clinical and laboratory studies for organ functions to determine eligibility must&#xD;
             be performed within 7 days prior to first dose of study drug unless otherwise&#xD;
             indicated below.&#xD;
&#xD;
          8. Patients must have adequate organ functions at the time of registration:&#xD;
&#xD;
               -  Hematological: Hematological recovery as defined by ANC ≥750/μL, platelets ≥30&#xD;
                  (non-transfused x 7 days)&#xD;
&#xD;
               -  Liver: Adequate liver function as defined by AST and ALT &lt;10x upper limit of&#xD;
                  normal&#xD;
&#xD;
               -  Renal: Adequate renal function defined as (perform one of the following):&#xD;
                  Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 or a serum&#xD;
                  creatinine based on age/gender&#xD;
&#xD;
          9. Females of childbearing potential must have a negative pregnancy test. Patients of&#xD;
             childbearing potential must agree to use an effective birth control method. Female&#xD;
             patients who are lactating must agree to stop breast-feeding.&#xD;
&#xD;
         10. Written informed consent in accordance with institutional and FDA guidelines must be&#xD;
             obtained from all subjects (or patients' legal representative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BSA of &lt;0.25 m2&#xD;
&#xD;
          2. Metastatic disease outside of CNS&#xD;
&#xD;
          3. Relapsed/refractory patients who are radiation-naïve and age 5 years or older at time&#xD;
             of enrollment&#xD;
&#xD;
          4. Investigational Drugs: Subjects who are currently receiving another investigational&#xD;
             drug are excluded from participation.&#xD;
&#xD;
          5. Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are&#xD;
             not eligible. Subjects must have fully recovered from the hematological and bone&#xD;
             marrow suppression effects of prior chemotherapy.&#xD;
&#xD;
          6. Infection: Subjects who have an uncontrolled infection are not eligible until the&#xD;
             infection is judged to be well controlled in the opinion of the investigator.&#xD;
&#xD;
          7. Subjects who, in the opinion of the investigator, may not be able to comply with the&#xD;
             safety monitoring requirements of the study, or in whom compliance is likely to be&#xD;
             suboptimal, should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beat Childhood Cancer at Atrium Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve Bergendahl, MSN</last_name>
    <phone>704.355.1220</phone>
    <email>genevieve.bergendahl@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon McKee</last_name>
    <phone>704.355.1220</phone>
    <email>sharon.mckee@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>501-364-2760</phone>
      <email>HallSF@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Neville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland-</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Effie Bourgin</last_name>
      <email>EBourgin@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Anurag Agrawal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Newton</last_name>
      <phone>860-545-9337</phone>
      <email>ANewton@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica El-Shami</last_name>
      <phone>321-841-8588</phone>
      <email>Jessica.El-Shami@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Don Eslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Children's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Manns</last_name>
      <email>Jennifer.Manns@baycare.org</email>
    </contact>
    <contact_backup>
      <last_name>Connie Nickerson</last_name>
      <email>connie.nickerson@baycare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Don Eslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital/University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Thomas</last_name>
      <email>Jennifer.Thomas@nortonhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael A Huang, MD</last_name>
      <phone>502.852.8450</phone>
      <email>michael.huang@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Huang A Michael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Dinkins</last_name>
      <phone>816-302-6893</phone>
      <email>MDinkins@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Keith August, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Maxwell, RN</last_name>
      <phone>314-268-4000</phone>
    </contact>
    <investigator>
      <last_name>William Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chreyl Falls</last_name>
      <email>Cheryl.Falls@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Derek Hanson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Moore</last_name>
      <phone>980-442-2356</phone>
      <email>Abigail.Moore@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Smith</last_name>
      <email>Lauren.Smith7@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Oesterheld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center and Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Treadway</last_name>
      <email>streadway@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Valerie Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sydney Bargeloh</last_name>
      <phone>843-792-2957</phone>
      <email>BROWNSY@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jaqueline Kraveka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Blood and Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhea Robinson, RN</last_name>
      <phone>512-628-1902</phone>
      <email>TXAUS-DL-SFCHemonc.research@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Virginia Harrod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.beatcc.org</url>
    <description>Beat Childhood Cancer Consortium website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Giselle SaulnierSholler</investigator_full_name>
    <investigator_title>Beat Childhood Cancer Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

